Effect of Itraconazole on the Pharmacokinetics of Ciprofloxacin in Healthy Volunteers
Main Article Content
Abstract
Itraconazole, a triazole antifungal agent, is a potent cytochrome P-450 inhibitor and
also a P-glycoprotein (P-gp) inhibitor. Ciprofloxacin, a fluoroquinolone compound with
broad spectrum antimicrobial activity, is often coadministered with an antifungal drug in
HIV-infected patients. The drug-drug interaction between itraconazole and ciprofloxacin may
occur in these patients. Therefore, the aim of this study was to investigate the effect of
itraconazole on the pharmacokinetics of ciprofloxacin following a multiple oral dose in
healthy volunteers. Two-phase crossover study with a 2 week washout period was designed
to study in six healthy volunteers. In phase 1, each volunteer received 500 mg of
ciprofloxacin twice daily for 7 days whereas in phase 2, they also received 500 mg
ciprofloxacin and 200 mg itraconazole twice daily for 7 days. The results revealed that there
was no significant difference in each ciprofloxacin pharmacokinetic parameter between 2
phases of study in six healthy volunteers. In conclusion, itraconazole co-administration with
ciprofloxacin did not alter the ciprofloxacin pharmacokinetics in healthy volunteers.
Article Details
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.
